- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01149733
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
August 18, 2010 updated by: Teva Pharmaceuticals USA
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
The objective of this study is to evaluate the comparative bioavailability between tamsulosin hydrochloride 0.4 mg capsules (Manufactured by Teva Pharmaceutical Industries Ltd.; distributed by Teva Pharmaceuticals USA) and Flomax® (tamsulosin hydrochloride)0.4
mg capsules (Manufactured by Yamanouchi Pharmaceutical Co., Japan; distributed by Boehringer Ingelheim Pharmaceutical Inc. USA), after a single-dose in healthy subjects under fed conditions.
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M1R 5A3
- Pharma Medica Research Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy, non-smoking male subjects, 18 years of age or older.
- BMI greater than or equal to 19 and less than or equal to 30.
Negative for:
- HIV.
- Hepatitis B surface antigen and Hepatitis C antibody.
- Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
- Urine cotinine test
- No significant diseases or clinically significant findings in a physical examination.
- No clinically significant abnormal laboratory values.
- No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram (ECG).
- Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between 60-90 mmgHg.
- Be informed of the nature of the study and given written consent prior to receiving any study procedure.
Exclusion Criteria:
- Known history or presence of any clinically significant medical condition, illness or surgery within 4 weeks prior to drug administration.
- Known or suspected carcinoma.
Known history or presence of:
- Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug substances with similar activity.
- Alcoholism within the last 12 months.
- Drug dependence and/or substance abuse.
- Use of tobacco or nicotine-containing products within the last 6 months.
- Use of any prescription medication within 14 days prior to Period 1 dosing. Use of any over the counter (OTC) medication within 7 days prior to Period 1 dosing.
- Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to Period 1 dosing.
- On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
- Participated in another clinical trial or received and investigational product within 30 days prior to drug administration.
- Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.
- Difficulty fasting or consuming the standard meals.
- Do not tolerate venipuncture.
- Unable to read or sign the ICF.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tamsulosin
0.4 mg Capsule
|
Test 0.4 mg Capsule
Reference Listed 0.4 Capsule
Other Names:
|
Active Comparator: Flomax®
0.4 mg Capsule
|
Test 0.4 mg Capsule
Reference Listed 0.4 Capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
Time Frame: Blood samples drawn over 60 hour period
|
Bioequivalence based on Cmax
|
Blood samples drawn over 60 hour period
|
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Time Frame: Blood samples drawn over 60 hour period
|
Bioequivalence based on AUC0-t
|
Blood samples drawn over 60 hour period
|
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
Time Frame: Blood samples drawn over 60 hour period
|
Bioequivalence based on AUC0-inf
|
Blood samples drawn over 60 hour period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2004
Primary Completion (Actual)
November 1, 2004
Study Completion (Actual)
November 1, 2004
Study Registration Dates
First Submitted
June 22, 2010
First Submitted That Met QC Criteria
June 22, 2010
First Posted (Estimate)
June 23, 2010
Study Record Updates
Last Update Posted (Estimate)
September 13, 2010
Last Update Submitted That Met QC Criteria
August 18, 2010
Last Verified
August 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004-823
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Tamsulosin
-
Hanmi Pharmaceutical Company LimitedCompletedBenign Prostate HyperplasiaKorea, Republic of
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedProstatic Hyperplasia
-
Lawson Health Research InstituteNot yet recruitingUrinary Retention PostoperativeCanada
-
Menoufia UniversityCompletedProstatic Neoplasms | Prostate Disease | Prostate Hypertrophy | Prostate ObstructionEgypt
-
Boehringer IngelheimCompleted
-
Samsung Medical CenterUnknown
-
Hackensack Meridian HealthRecruitingUrinary RetentionUnited States
-
Astellas Pharma China, Inc.CompletedHealthy | Pharmacokinetics of Tamsulosin HydrochlorideChina
-
CHU de Quebec-Universite LavalFédération des médecins résidents du QuébecNot yet recruitingColorectal Surgery | Urinary Retention | Post-operative Urinary Retention | Rectal Resection | TamsulosinCanada